Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with Massdevice +3.
This week President Barack Obama is expected to sign a patent reform bill marking the most dramatic changes to the patent system in decades, drawing adulation and ire from varying sectors of the innovation economy.
Johnson & Johnson (NYSE:JNJ) is mulling a move into the market for heart pumps and heart valves, for the right price, according to CFO Dominic Caruso.
Boston Scientific Corp. (NYSE:BSX) poached Johnson & Johnson (NYSE:JNJ) med-tech executive Michael Mahoney to fill the corner office as J. Raymond Elliot prepares to step down. In an investors’ meeting, company officials outlined BSX’s plan to devote capital to mergers and stock repurchasing, and ever-feisty Elliot flamed the med-tech tax that’s part of President Barack Obama’s landmark health reform law today.